Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 2Recruiting 2Active not recruiting 2Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 29Urinary Bladder Neoplasms 15Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Pancreatic Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Ovarian Neoplasms 11Sarcoma 10Hodgkin Disease 10Glioblastoma 10Carcinoma, Transitional Cell 10Rectal Neoplasms 9Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Kidney Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Breast Neoplasms 7Head and Neck Neoplasms 6Skin Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5

Interventions

pembrolizumab 6Paclitaxel 5Carboplatin 4Bevacizumab 3oregovomab 2Nivolumab 2Hyperthermic Intraperitoneal Chemotherapy 2Cisplatin 2tislelizumab 1spartalizumab 1rucaparib 1olaparib 1niraparib 1lenvatinib 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1anlotinib 1Surveys and Questionnaires 1Saline Solution 1Ramucirumab 1Platinum 1Nutrition Assessment 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Immunotherapy, Adoptive 1Glucose 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Ovarian Epithelial × Nivolumab × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡